CLEAN : France at odds with

The video discusses the struggle to secure medical rights and the role of evaluation councils. It highlights the lack of additional benefits of third generation pills over second generation ones, questioning their reimbursement. The video also covers pharmaceutical marketing tactics and recommends limiting third generation pills to second intention prescriptions. Finally, it suggests regulatory actions to restrict market authorization of these pills.

Comment les laboratoires pharmaceutiques ont-ils promu les nouveaux médicaments?

Quelles actions la demande de l'Agence nationale de la sécurité du médicament implique-t-elle?